Li-wu Fu, Ph.D., Professor, Doctoral Supervisor. Prof. Fu obtained his PhD in the field of Cancer Pharmacology from the Sun Yat-sen University and carried out his doctoral research in South Carolina Medical University from 1999 to 2001.

Prof. Fu’s field of expertise includes anticancer drug pharmacology, molecular mechanism of anticancer drugs and individual cancer chemotherapy. In recent years, he mainly focused on the study of molecular mechanism of anti-cancer drugs, drug resistance of cancer cells (especially multidrug resistance), the innate resistance of cancer stem cells and the individual cancer chemotherapy. For the excellent work in the research of “Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells”, Prof. Fu’s team gained the first prize of “Chinese Anti-Cancer Association (CACA) Science and Technology Award” (Ranked first) and the second prize of “Institute of Higher Education Outstanding Scientific Research Achievements Award” (Natural Science Award) in 2011.

As the leader of the research group, he has won the provincial and ministerial level scientific and technological awards for several times, including the “Outstanding young scientific and technological talents award from Ministry of Health”, the “Servier outstanding young workers Pharmacology Award” and the “Ding Ying Science Award” in 2011.

Prof. Fu has presided over and successfully completed more than 40 key research projects on national, provincial and ministerial scale and horizontal fund projects.

More than 200 research papers have been published and up to 100 papers have been published in high-quality SCI journals, including Cancer Res (6 articles), Oncotarget, Mol Med, Cell Cycle, Eur J Cancer, Mol Cancer Ther, Birth J Parmacol, Biochem Pharmacol , Mol Pharmacol etc. and 10 invention patents have been attained.

Drug resistance in tumor，Tumor pharmacology，Individualized treatment

1999.1.-2002.1.Postdoctoral Fellow

Department of Pathology and Lab Medicine, Medical University of South Carolina.

Charleston, USA.

1993.9.-1996.7. Ph.D. Program of Medicine

Cancer Center, Sun Yat-Sen University of Medical Sciences (SUMS), (now rename to:Sun Yat-senUniversity), Guangzhou, 510060,P. R.China.

1990.9.-1993.7. M.S. Program of Medicine

Department of Toxicology, Sun Yat-Sen University of Medical Sciences (SuMS), (nowrename to: Sun Yat-sen University), Guangzhou, 510080 P. R. China.

1982.9.-1987.7. M.D.,

Department of Medicine, Guangdong Medical and Pharmaceutical College (renameto Guangdong pharmaceutical College since 1993), Guangzhou, 510024 P.R.China.

1、Wu S, Luo M, To KKW, Zhang J, Su C, Zhang H, An S, Wang F, Chen D, Fu L*. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. Mol Cancer. 2021 Jan 18;20(1):17. IF: 41.4

2、Zhang H#, Xia Y#, Wang F#, Luo M, Yang K, Liang S, An S, Wu S, Yang C, Chen D, Xu M, Cai M, To KKW, Fu L*. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression. Adv Sci (Weinh). 2021 Mar 24;8(10):2003404.

3、Luo M, Wang F, Zhang H, To KKW, Wu S, Chen Z, Liang S, Fu L*. Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer. Signal Transduct Target Ther. 2020 Aug 28;5(1):141. IF: 38.1

4、Wang F, Qi XM, Wertz R, Mortensen M, Hagen C, Evans J, Sheinin Y, James M, Liu P, Tsai S, Thomas J, Mackinnon A, Dwinell M, Myers CR, Bartrons R, Fu L*, Chen G*. p38gamma MAPK is essential for aerobic glycolysis and pancreatic tumorigenesis. Cancer Res.2020 Jun 24:3281.

5、Wang X, Qiao D, Chen L, Xu M, Chen S, Huang L, Wang F, Chen Z, Cai J, Fu L*. Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance. Mol Cancer. 2019 Dec 12;18(1):182.

6、Yang C, Wang X, To KKW, Cui C, Luo M, Wu S, Huang L, Fu K, Pan C, Liu Z, Fan T, Yang C, Wang F*, Fu L*. Circulating tumor cells shielded with extracellular vesicle-derived CD45 evade T cell attack to enable metastasis. Signal Transduct Target Ther. 2024 Apr 5;9(1):84.

7、Yang K#, Fu K#, Zhang H, Wang X, To KKW, Yang C, Wang F, Chen ZS, Fu L*. PBA2, a novel inhibitor of the beta-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.  Mol Cancer. 2024 Sep 28;23(1):209.

8、Luo M, Wang X, Wu S, Yang C, Su Q, Huang L, Fu K, An S, Xie F, To KKW, Wang F, Fu L*. A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block "eat-me" signal. Signal Transduct Target Ther. 2023 Aug 23;8(1):312.